Adding Keytruda (pembrolizumab) to standard first-line chemotherapy significantly extends the survival of people with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer, and also significantly lowers their risk of disease progression or death, according to interim data from a Phase 3 trial. Notably, these benefits were seen across multiple patient subgroups, regardless of PD-L1 status and cancer subtype. The combination also increased the proportion of responders in the overall population enrolled in the…
You must be logged in to read/download the full post.
The post Keytruda Combo Shown to Extend Survival in Advanced Esophageal, GEJ Cancers appeared first on BioNewsFeeds.